SynthesisBrain and behavior2019
The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.
Synthesis in Brain and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06216886 (Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.), which is not on this map. Cited by 26 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.
Who cites it
26 citing papers in PubMed, 7 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain.Scientific reports · 2024Pooled it
- Interventions for treating pain and disability in adults with complex regional pain syndrome- an overview of systematic reviews.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain.Toxins · 2022Pooled it
- Pooled it
- Efficacy and Safety of Moxibustion for Postherpetic Neuralgia: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.Brain and behavior · 2019Pooled it
- Trigger zones in trigeminal neuralgia: clinical features, pathophysiological mechanisms, and therapeutic strategies.Frontiers in neurology · 2026Review
- The efficacy of botulinum toxin in neuropathic pain: a systematic review.British journal of pain · 2024Article
- Article
- Bilateral trigeminal neuralgia due to bilaterally duplicated superior cerebellar arteries.BMJ case reports · 2024Article
- Effectiveness of Botulinum Toxin in the Treatment of Neuropathic Pain: A Literature Review.Cureus · 2023Review
- Pharmacological Management of Orofacial Pain.Drugs · 2023Review
- Article
- [Clinical use of botulinum toxin type A in pain medicine].Schmerz (Berlin, Germany) · 2023Article
- The potential role of T-cell metabolism-related molecules in chronic neuropathic pain after nerve injury: a narrative review.Frontiers in immunology · 2023Review
- The Utility ofInternational journal of environmental research and public health · 2022Review
- A clinical review of the use of Botulinum Toxin type A in managing central neuropathic pain in patients with spinal cord injury.The journal of spinal cord medicine · 2022Review
- Update on Interventional Management of Neuropathic Pain: A Delphi Consensus of the Spanish Pain Society Neuropathic Pain Task Force.Medicina (Kaunas, Lithuania) · 2022Article
- Acute and Chronic Pain from Facial Skin and Oral Mucosa: Unique Neurobiology and Challenging Treatment.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough recent studies have shown that botulinum toxin-A (BTX-A) has a good analgesic effect on trigeminal neuralgia (TN) and peripheral neuropathic pain (PNP), the quality of evidence is low due to limited data. This meta-analysis is used to synthesize existing evidence for the treatment of these conditions with BTX-A.
methodsRelevant trials were accessed by using an electronic search in databases (Web of Science, PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov). Data from included randomized controlled trials (RCTs) on the efficacy and safety of BTX-A in treating TN and PNP were extracted for meta-analysis.
resultsFinally, 10 RCTs (n = 391) were included in this meta-analysis. The pooled effect of BTX-A was superior to placebo based on pain intensity (SMD = -0.48, 95% CI [-0.74, 0.23] at 1 month, SMD = -0.58, 95% CI [-0.91, -0.24] at 2 months, and SMD = -0.55, 95% CI [-0.87, -0.22] at 3 months). Number needed to treat (NNT) for 50% pain intensity reduction showed better effect of BTX-A on TN and postherpetic neuralgia (PN). Adverse events associated with BTX-A were similar to placebo (OR = 1.58, 95% CI [0.51, 4.87], p = .424).
conclusionPooled data from our meta-analysis suggest that BTX-A is efficacious and safe in treating TN and PNP. However, due to the limited sample size and heterogeneity, further larger and well-designed RCTs are imperative to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.